日本久久久久久免费网络_午夜无码国产理论在线_97一区二区在线_婷婷六月激情综合_欧美日韩精品在线看_国产福利在线观看_国产精品天仙tv在线观看_日本情趣视频日韩中文字幕视频在线观看_全国免费黄色网址_日韩岛国AV免费_在线观看无码91av_熟女人妻在线播放_亚洲中文日本在线观看_亚洲国产欧美在线_亚洲一区二区在线国产 ,亚洲精品6久久久久中文字幕_免费人成网址在线观看国内_日韩亚洲制服丝袜中文字幕_亚洲av不卡电影_国产精品成人999_亚洲激情综合_日韩欧美在线视频_99久久精品毛片亚洲一区二区三区四区免费电影_一级av在线播放_免费毛片永久看_亚洲区色_国产精品影院久久_手机在线观看国产精品_一区二区视频日韩免费_一级风流片a级国产 ,美女啪啪无遮挡_国产精品丝袜无码不卡一区_色吊丝永久性观看网站_98成人在线_亚洲噜噜噜噜噜噜久久_韩国三级免费观看_久久久久性色AV毛片特级_久久三级国产国产精品原创永久在线观看_谁有免费黄色网址_国产AV综合AV一区二区三区_a片觀看_人妻斩福利导航_日韩电影一区二区三区在线观看_亚洲综合区欧美一区二区

Join Pharmaron's DMPK Webinar Series on "New DMPK Screening and Development Strategies for CNS Candidate Compounds." Hear from experts Margareta Hammarlund-Udenaes, Ph.D., Danxi Li, Ph.D., and Elnaz Gozalpour, Ph.D. as they explore Preclinical ADME studies in bioanalytical development.

Capabilities

Recorded: January 2023

This webinar discussed the concept of Kp,uu as a measure of CNS penetration along with the different methodologies available to assess CNS penetration and highlight the complexities of translation of this to human.

Register to watch our webinar on-demand

You can ask your own questions of our experts.

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State

Email(Required)

Thank you for registering to watch our on-demand webinar. By submitting this form, you consent to the collection and processing of your personal data by Pharmaron in accordance with our Privacy Policy. You may be contacted by email following your webinar viewing regarding any questions you may have, as well as relevant services and updates. You can unsubscribe or withdraw your consent at any time.

Agenda:

Introduction to the brain and BBB
- Brain physiology, blood flow and fluid compartments;
- Mechanisms of drug passage across BBB
- “Free drug theory”
- Importance of the Kp,uu concept
Predicting and measuring drug brain exposure
- In vitro methods for assessing BBB permeability;
- In vivo methods to measure brain exposure;
- Methods to measure unbound brain concentration – current findings and challenges;
Pharmacokinetics of brain exposure and translation to humans
- In vitro to in vivo extrapolation of Kp,uu to human – current findings and challenges
- Existing cell-based models representing BBB
- CNS penetration of drugs across different species

Meet our Speakers

Moderated by:

Chris Bode – VP of Scientific Affairs at Pharmaron

Speakers:

Margareta Hammarlund-Udanaes, Ph.D. – Professor of Pharmacokinetics and Pharmacodynamics at Uppsala University

Margareta Hammarlund-Udenaes, PhD, is a Professor of Pharmacokinetics and Pharmacodynamics at Uppsala University, Sweden, since 1999, Professor Emerita since 2020. She has supervised 20 PhD’s and published more than 130 original articles. She is an Editor of the book Drug Delivery to the Brain – Principles, Methodology and Applications (Springer, 2014; 2^nd Ed 2022). Her h-index is 53 (Google Scholar). She was the Dean of the Faculty of Pharmacy at Uppsala University 2017-2020.

Dr Hammarlund-Udenaes became a Fellow of the American Association of Pharmaceutical Scientists in 2005, became an International Fellow of the Academy of Pharmaceutical Science and Technology in Japan in 2015, and an Honorary Member of the Swedish Academy of Pharmaceutical Sciences in 2016. She also received the Ar?ens Award in Pharmacology in the Netherlands in 2021 for her scientific achievements. She is a former Associate Editor of Pharmaceutical Research, former EAB member of the Journal of Pharmaceutical Sciences and presently an EAB member of Fluids and Barrier of the CNS. Among others, she was the Chair of the Gordon Conference on Barriers of the CNS in 2014 and of the 8^th International Symposium on Microdialysis in 2016, and is co-organizing the 14^th Cerebrovascular Biology meeting to be held in Uppsala 2023.

The main scientific interest of Dr Hammarlund-Udenaes is drug delivery to the brain, based on pharmacokinetic-pharmacodynamic principles with a translational perspective. This is a critical area for pharmaceutical research, because of the severe limitations imposed on the development of drugs for the CNS by the blood-brain barrier (BBB). The work to date has resulted in new innovative methods to measure brain drug delivery in discovery and development settings. It has revealed basic relationships of BBB function and brain physiology regarding the transport of exogenous compounds and has provided a new understanding of how drugs are handled by the BBB and the brain. Disease influence and the role of nanodelivery on BBB transport of drugs and peptides are also investigated.

Danxi Li, Ph.D. – Senior Director, in vitro ADME at Pharmaron

Dr. Li is working as one of the main study directors of in vitro ADME department at Pharmaron and leading an experienced team to support various sponsors from early screening to regulatory submission. As ADME project coordinator, she helps sponsors to establish many specific assay platforms in Pharmaron, provides scientific input to optimize assay systems and ensures high quality data submission in a time efficient way. Before joining Pharmaron in early 2011, Dr. Li has worked at University of Medicine and Dentistry in New Jersey, USA, for 2 years as a visiting researcher. Her research work there focused on functionality investigation of CYP polymorphism using transfected cell models, which was continued work from her Ph.D. thesis work at Zhejiang University in China.

Elnaz Gozalpour, Ph.D. – Associate Director, DMPK at Pharmaron

Elnaz joined Pharmaron in June 2022 as an Associate Director in DMPK team of Drug Discovery. Prior to this, she was an Associate Principal Scientist in ADME/DMPK at AstraZeneca, Cambridge, U.K. In her previous position, she was supporting drug discovery projects at preclinical stages across Oncology, Neuroscience and Cardiovascular therapeutic areas. Elnaz joined AZ after finishing her Ph.D. in Molecular Pharmacology at Radboud university medical centre of Nijmegen (The Netherlands). She completed her undergraduate (BSc and MSc) in Molecular Biology and Human Genetics, respectively at Tehran University, Iran.

Elnaz has experience in ADME and DMPK in vitro sciences, drug transporters, and DDI. She is particularly interested in the application of innovative in vitro models of kidney and BBB to investigate and improve in vitro-in vivo extrapolation (IVIVE), interspecies differences and PB-PK modeling. During her time at AstraZeneca (AZ), she was leading the establishment of renal model using 3D microfluidic systems at AZ and Loughborough university. Being DMPK lead in Neuroscience projects, she has had a strong impact on the implementation of CNS strategy for distinct species. She is also interested to study polymorphisms of drug transporters and their association with ADME in different populations.

Elnaz has been a member of the American Association of Pharmaceutical Scientists (APSS), Drug metabolism and discussion group (DMDG) and Federation of European Biochemical Societies (FEBS). She has given a number of poster and podium presentations at the meetings and conferences of the above-mentioned societies. She has also contributed to the recent white paper of the International Transporters Consortium (ITC) on drug transporters in 2022.